AstraZeneca announced a collaboration with Accent Therapeutics for research, development and commercialization of innovative medicines that have an impact on RNA-modifying proteins in the treatment of cancer.
The cooperation of companies focused on targeted therapies aimed at RNA-modifying proteins that control various aspects of the biology of RNA. This is a new approach to fixing the processes that can lead to cancer or drug resistance.
Under the agreement, Accent Therapeutics will be responsible for research and development in the framework of pre-clinical studies and completion of clinical trials of phase I. After the end of the first stage of AstraZeneca will lead the development and commercialization of this program, and Accent Therapeutics will have the opportunity to develop and commercialize jointly with AstraZeneca in the United States. AstraZeneca will also receive an exclusive option to license worldwide rights to two additional programs in preclinical studies for which Accent Therapeutics will perform a series of pre-clinical activities.